Maskell, Peter D., De Paoli, Giorgia, Nitin Seetohul, L. and Pounder, Derrick J. (2012) Phenazepam: The drug that came in from the cold. Journal of Forensic and Legal Medicine, 19 (3). pp. 122-125. ISSN 1752928X
Abstract

Phenazepam [7-bromo-5-(2-chlorophenyl)-1, 3-dihydro-2H-1,4-benzodiazepine-2-one], sometimes called fenazepam (Fig. 1A), is part of the 1,4-benzodiazepine group of benzodiazepines along with drugs such as diazepam, nordazepam, oxazepam and temazepam. It is however one of very few of the 1,4-benzodiazepine group to contain a bromine atom, along with the active form of gidazepam, another soviet-developed benzodiazepine5 and bromazepam. As with other benzodiazepines, it is used clinically for its anxiolytic, anticonvulsant, muscle-relaxing and sedating properties,6 and is available as 0.5-mg and 1-mg tablets,6 injectable solutions (0.1%, 0.3%) or transdermal patches (Phenopercuten).7 Clinically the dose of phenazepam that is given depends on what condition is being treated but does not exceed 10 mg day−1, and is usually not more than 5 mg day−1. Illicitly, phenazepam has been reported being sold as a powder, tablets, in the USA, spiked in lysergic acid diethylamide (LSD) mimic blotters8 and 9 and in New Zealand phenazepam has been found in a synthetic cannabinoid mix called ‘Kronic’.10 Reported recreational doses of phenazepam are around 2–10 mg, but sometimes more.8

Information
Library
Statistics
Add to AnyAdd to TwitterAdd to FacebookAdd to LinkedinAdd to PinterestAdd to Email